https://www.bioworld.com/rss en-us There is no doubt that investment into women’s health is increasing. According to a new report by W Group, in 2025, $1.55 billion in disclosed equity was raised by 85 women’s health companies, across more than 30 countries. However, challenges remain. http://www.bioworld.com/articles/732611 Wed, 15 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732611-womens-health-investment-climbs-but-funding-challenges-remain Businesswoman pressing dollar sign on touchscreen Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive eating behaviors. No effective therapy is currently available. At a symposium held during the recent FENS Forum in Barcelona, several leading researchers with decades of experience in AN presented findings that further strengthen the growing body of evidence supporting the disorder’s metabolic component. http://www.bioworld.com/articles/732624 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732624-rethinking-anorexia-a-disorder-of-mind-and-metabolism Photo of scale with woman sitting on floor holding head and arms on knees Regenerative medicine company Bellaseno GmbH is accelerating development of its absorbable breast scaffold, with a pivotal Australian trial recruiting faster than expected and a newly announced licensing deal with Johnson & Johnson subsidiary Mentor Worldwide LLC positioning the technology for global commercialization. http://www.bioworld.com/articles/732474 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732474-bellaseno-speeds-breast-scaffold-trial-as-j-and-j-deal-clears-path-to-market Illustration of Bellaseno's scaffold placed in the breast Bellaseno’s regenerative absorbable breast scaffold. Credit: Bellaseno. Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s architecture is shaped through the organization of tissues, the establishment of molecular pathways, and the coordination of signals that will later sustain the body as an integrated system. It is likely the most delicate stage of life, where any disturbance in that foundational process can have lasting consequences on health. http://www.bioworld.com/articles/732374 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732374-cinp-2026-prenatal-and-adolescent-stress-shape-brain-vulnerability Regenerative medicine company Bellaseno GmbH is accelerating development of its absorbable breast scaffold, with a pivotal Australian trial recruiting faster than expected and a newly announced licensing deal with Johnson & Johnson subsidiary Mentor Worldwide LLC positioning the technology for global commercialization. http://www.bioworld.com/articles/732275 Thu, 02 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732275-bellaseno-speeds-breast-scaffold-trial-as-j-and-j-deal-clears-path-to-market Illustration of Bellaseno's scaffold placed in the breast Bellaseno’s regenerative absorbable breast scaffold. Credit: Bellaseno. Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described tachykinin NK3 receptor antagonists that are potentially useful for the treatment of menopausal symptoms, polycystic ovarian syndrome, uterine fibroids (myoma), schizophrenia, irritable bowel syndrome and breast cancer. http://www.bioworld.com/articles/732121 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732121-hansoh-identifies-new-nk3-receptor-antagonists Harnessing an oncolytic signal and redirecting it against the tumor itself could be developed as a selective strategy for certain cancer types, as occurs with ErbB hyperactivity, a form of signaling that drives many carcinomas. Inspired by this idea, scientists at Stanford University have engineered a virus that replicates only in ErbB-hyperactive ovarian cancer cells. This allowed them to precisely kill this specific tumor population, achieving greater efficacy and safety than previous oncolytic viruses. http://www.bioworld.com/articles/731852 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731852-signal-rewiring-turns-ovarian-cancer-against-itself Illustration of cancer on ovary Mammogen Inc. raised $30 million in equity financing in a series A round to support the clinical advancement and commercialization of its RNA-powered molecular diagnostics platform. The company’s lead product is Gentru-breast, a blood-based assay designed to detect molecular signatures associated with breast cancer from a simple blood draw. http://www.bioworld.com/articles/731541 Wed, 03 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731541-mammogen-raises-30m-for-blood-based-breast-cancer-detection-assay Dollar sign between hands Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. http://www.bioworld.com/articles/731648 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731648-trop2-adcs-progress-into-first-line-for-lung-breast-cancers Floating antibody drug conjugates Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. http://www.bioworld.com/articles/731444 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731444-trop2-adcs-progress-into-first-line-for-lung-breast-cancers Floating antibody drug conjugates WAVES, an algorithm designed to extract menstrual-cycle metrics from physiological signals such as basal body temperature, which oscillates with sex hormones, shows how different parameters change with age and helps determine whether each person maintains a stable individual pattern or personal footprint. A study based on data from 5,674 cycles from 753 women demonstrates through this tool that age is associated with higher temperatures, shorter cycles, and greater irregularity. In addition, several metrics show within-person stability, suggesting they could serve as personalized health markers. http://www.bioworld.com/articles/731248 Fri, 22 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731248-menstrual-footprints-may-act-as-broad-personal-health-markers Female uterus and ovaries on abstract scientific background Data from the All Women clinical trial, which looked at the Allegra transcatheter aortic valve replacement (TAVR) system compared to balloon-expandable valves (BEV) in women with aortic stenosis, showed that Allegra delivered lower mean gradients and less prosthesis-patient mismatch than BEVs. The data presented at the EuroPCR conference in Paris was the first randomized head-to-head comparison of different TAVR platforms conducted exclusively in women. http://www.bioworld.com/articles/731340 Wed, 20 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731340-all-women-data-show-allegra-edge-in-female-tavr-patients Biosensors International Allegra transcatheter heart valve Allegra transcatheter heart valve. Credit: Biosensors International Maipl Therapeutics Inc. has outlined preclinical progress with MA-4604, its lead investigational therapy for endometriosis. http://www.bioworld.com/articles/731123 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731123-maipl-therapeutics-advances-ma-4604-for-endometriosis Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc. http://www.bioworld.com/articles/730787 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc. http://www.bioworld.com/articles/730643 Mon, 27 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b Three red darts on target Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions and cell types. Scientists at the National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) used single-cell sequencing and unveiled distinct gene expression patterns regulated by hormones and sex chromosomes. This detailed map of the brain’s molecular biology shows how women and men switch on and off more than 3,000 brain genes differently and expands the catalogue of X chromosome genes that escape inactivation. http://www.bioworld.com/articles/730447 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730447-sex-differences-shape-gene-activity-across-the-human-brain Brain and DNA There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking 157,159 participants in the UK Biobank over 13 years. This shows that even in the absence of any metabolic disturbance such as elevated lipids, high blood pressure or diabetes, there is an increased risk of heart attack, stroke, peripheral arterial disease, heart failure and liver disease in people with a body mass index over 30. http://www.bioworld.com/articles/730369 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730369-fit-and-fat-study-shows-no-such-thing-as-metabolically-healthy-obesity Woman exercising with hand weights There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking 157,159 participants in the UK Biobank over 13 years. This shows that even in the absence of any metabolic disturbance such as elevated lipids, high blood pressure or diabetes, there is an increased risk of heart attack, stroke, peripheral arterial disease, heart failure and liver disease in people with a body mass index over 30. http://www.bioworld.com/articles/730222 Fri, 10 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730222-fit-and-fat-study-shows-no-such-thing-as-metabolically-healthy-obesity Woman exercising with hand weights Changchun Genescience Pharmaceuticals Co. Ltd. has prepared and tested new steroid compounds acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors that are potentially useful for the treatment of endometriosis. http://www.bioworld.com/articles/730068 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730068-changchun-genescience-pharmaceuticals-discloses-new-17-hsd1-inhibitors Certain cancers, such as triple-negative breast cancer, produce antibodies that, although they help fight the tumor, can cross the blood-brain barrier and alter the function of NMDA receptors (NMDAR) in the brain, which are essential for neuronal signaling. Scientists at Cold Spring Harbor Laboratory (CSHL) have identified their origin and described how this process is linked to the maturation of these antibodies, which can activate or inhibit the receptor, causing neurological and psychiatric symptoms. http://www.bioworld.com/articles/730035 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730035-antitumoral-antibodies-cross-the-bbb-and-alter-brain-signaling Antibodies and synaptic neuron Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis. http://www.bioworld.com/articles/729879 Wed, 25 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729879-insilico-medicine-and-aska-enter-gynecological-collaboration Futuristic medical hologram illustration featuring the female reproductive system Endomet Biosciences Inc. (dba Endocyclic Therapeutics) has obtained IND clearance from the FDA for its lead program, ENDO-205, a first-in-class, nonhormonal targeted peptide therapeutic for endometriosis. http://www.bioworld.com/articles/729860 Tue, 24 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729860-endocyclics-endo-205-gains-ind-clearance-for-endometriosis Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated microglia and astrocytes, altered receptors such as TREM2, mitochondrial dysfunction, epigenetic changes and cerebrovascular alterations all seem to contribute to the development of dementia in Alzheimer’s disease (AD). While scientists attempt to address each of these elements, prevention is growing as a primary goal. http://www.bioworld.com/articles/729688 Wed, 18 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729688-adpd-2026-can-we-prevent-dementia-scientists-quantify-it MRI image brain on black background A study involving a small cohort of women who have received womb transplants has cast fresh light on how the immune system shapes pregnancy outcomes, opening up new avenues of research into implantation failure, preeclampsia and preterm birth. Using an array of single cell analyses, scientists at the University of Alabama at Birmingham (UAB) studied the composition and gene expression profiles of immune cells in tissue samples from five women who had received womb transplants. http://www.bioworld.com/articles/729643 Thu, 12 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729643-uterus-transplants-show-how-immune-cells-shape-pregnancy-outcomes Pregnancy A study involving a small cohort of women who have received womb transplants has cast fresh light on how the immune system shapes pregnancy outcomes, opening up new avenues of research into implantation failure, preeclampsia and preterm birth. http://www.bioworld.com/articles/729466 Wed, 11 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729466-uterus-transplants-show-how-immune-cells-shape-pregnancy-outcomes Pregnancy China’s National Medical Products Administration has approved Asieris Pharmaceuticals Co. Ltd.’s cold light photodynamic drug-device combination product, Cevira (APL-1702, hexaminolevulinate hydrochloride), which is used as a nonsurgical therapy for treating patients with cervical intraepithelial neoplasia grade 2. http://www.bioworld.com/articles/729585 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729585-china-approves-first-noninvasive-therapy-for-cervical-precancer Fallopian tubes, ovaries and uterus China’s National Medical Products Administration has approved Asieris Pharmaceuticals Co. Ltd.’s cold light photodynamic drug-device combination product, Cevira (APL-1702, hexaminolevulinate hydrochloride), which is used as a nonsurgical therapy for treating patients with cervical intraepithelial neoplasia grade 2. http://www.bioworld.com/articles/729303 Wed, 04 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729303-china-approves-first-noninvasive-therapy-for-cervical-precancer Fallopian tubes, ovaries and uterus A therapeutic strategy based on alternative splicing of the MECP2 gene could restore protein levels in Rett syndrome, a neurological disorder caused by mutations in that gene. Scientists at Baylor College of Medicine have successfully tested this approach both in vitro in neurons from Rett patients that produce some functional protein, correcting the altered gene expression and improving neuronal functions, and in vivo in mice. http://www.bioworld.com/articles/729322 Wed, 04 Mar 2026 07:00:00 -0500 https://www.bioworld.com/articles/729322-alternative-splicing-strategy-shows-promise-for-rett-syndrome Illustration of X chromosomes with DNA In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer. http://www.bioworld.com/articles/729321 Tue, 03 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729321-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china Cancer tumor in breast illustration In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer. http://www.bioworld.com/articles/729258 Fri, 27 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729258-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china Cancer tumor in breast illustration